Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by AMP Capital Investors Ltd

AMP Capital Investors Ltd boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,753 shares of the biopharmaceutical company’s stock after buying an additional 8,487 shares during the period. AMP Capital Investors Ltd’s holdings in Regeneron Pharmaceuticals were worth $13,751,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Fieldpoint Private Securities LLC purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth about $130,000. Sterling Investment Advisors Ltd. increased its stake in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the period. FNY Partners Fund LP increased its stake in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the period. IFP Advisors Inc increased its stake in Regeneron Pharmaceuticals by 33.2% during the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth about $206,000. Hedge funds and other institutional investors own 66.67% of the company’s stock.

REGN has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Jefferies Group restated a “hold” rating and set a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, September 29th. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 31st. Finally, Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $467.84.

In other news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $380.78 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $40,140.29, a P/E ratio of 32.35, a P/E/G ratio of 1.47 and a beta of 1.53. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $340.09 and a fifty-two week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the company posted $3.13 earnings per share. equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by AMP Capital Investors Ltd” was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://weekherald.com/2017/12/10/regeneron-pharmaceuticals-inc-regn-shares-bought-by-amp-capital-investors-ltd.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply